Analysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorPASSERO, Luiz Felipe Domingues
dc.contributor.authorMARQUES, Claudia
dc.contributor.authorVALE-GATO, Ines
dc.contributor.authorCORBETT, Carlos Eduardo Pereira
dc.contributor.authorLAURENTI, Marcia Dalastra
dc.contributor.authorSANTOS-GOMES, Gabriela
dc.date.accessioned2013-07-30T15:15:05Z
dc.date.available2013-07-30T15:15:05Z
dc.date.issued2012
dc.description.abstractLeishmania (Viannia) shawi causes cutaneous lesions in humans. Parasite antigens conferring significant protection against American tegumentar leishmaniosis (ATL) might be important for the development of effective vaccine. Therefore, this work evaluates the protective effect of antigenic fractions released by L. shawi. Antigens released by promastigotes to culture medium were concentrated and isolated by SDS-PAGE. The three main fractions LsPass1 (>75 kDa), LsPass2 (75-50 kDa) and LsPass3 (<50 kDa) were electro-eluted according with their molecular mass. Immunized BALB/c mice were challenged with L. shawi promastigotes and the course of infection monitored during 5 weeks. LsPass1-challenged mice showed no protection, however, a strong degree of protection associated to smaller lesions and high expression of IFN-gamma and TNF-alpha by CD4(+) T, CD8(+) T and double negative CD4CD8 cells was achieved in LsPass3-challenged mice. Furthermore, LsPass2-challenged mice showed an intermediated degree of protection associated to high levels of IFN-gamma, IL-4 and IL-10 mRNA. In spite of increased expression of IFN-gamma and TNF-alpha, high amounts of IL-4 and IL-10 mRNA were also detected in LsPass3-challenged mice indicating a possible contribution of these cytokines for the persistence of a residual number of parasites that may be important in inducing long-lasting immunity. Therefore, LsPass3 seems to be an interesting alternative that should be considered in the development of an effective vaccine against ATL.
dc.description.indexMEDLINE
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2007/56209-4, 07/50654-6]
dc.description.sponsorship[FMUSP-HC/LIM-50]
dc.description.sponsorshipPortuguese Foundation for Science and Technology (FCT)
dc.description.sponsorshipEuropean Union [PTDC/CVT/70275/2006]
dc.identifier.citationARCHIVES OF DERMATOLOGICAL RESEARCH, v.304, n.1, p.47-55, 2012
dc.identifier.doi10.1007/s00403-011-1171-7
dc.identifier.issn0340-3696
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1002
dc.language.isoeng
dc.publisherSPRINGER
dc.relation.ispartofArchives of Dermatological Research
dc.rightsrestrictedAccess
dc.rights.holderCopyright SPRINGER
dc.subjectLeishmania shawi
dc.subjectReleased antigens
dc.subjectImmunization
dc.subject.othergrowth-factor-beta
dc.subject.othercutaneous leishmaniasis
dc.subject.otherimmune-response
dc.subject.otheramazonian brazil
dc.subject.othert-cells
dc.subject.othersp-n
dc.subject.otherbalb/c mice
dc.subject.otherpara-state
dc.subject.otherifn-gamma
dc.subject.otherinfection
dc.subject.wosDermatology
dc.titleAnalysis of the protective potential of antigens released by Leishmania (Viannia) shawi promastigotes
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryPortugal
hcfmusp.affiliation.countryisopt
hcfmusp.author.externalMARQUES, Claudia:Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, Unidade Ensino & Invest Parasitol Med, P-1200 Lisbon, Portugal
hcfmusp.author.externalVALE-GATO, Ines:Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, Unidade Ensino & Invest Parasitol Med, P-1200 Lisbon, Portugal
hcfmusp.author.externalSANTOS-GOMES, Gabriela:Ctr Malaria & Outras Doencas Trop, IHMT, Unidade Ensinno & Invest Parasitol Med, P-1349008 Lisbon, Portugal; Univ Nova Lisboa, Inst Higiene & Med Trop, Ctr Malaria & Outras Doencas Trop, Unidade Ensino & Invest Parasitol Med, P-1200 Lisbon, Portugal
hcfmusp.citation.scopus3
hcfmusp.contributor.author-fmusphcLUIZ FELIPE DOMINGUES PASSERO
hcfmusp.contributor.author-fmusphcCARLOS EDUARDO PEREIRA CORBETT
hcfmusp.contributor.author-fmusphcMARCIA DALASTRA LAURENTI
hcfmusp.description.beginpage47
hcfmusp.description.endpage55
hcfmusp.description.issue1
hcfmusp.description.volume304
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed21882046
hcfmusp.origem.scopus2-s2.0-84857055053
hcfmusp.origem.wosWOS:000303405200007
hcfmusp.publisher.cityNEW YORK
hcfmusp.publisher.countryUSA
hcfmusp.relation.referenceBogdan C, 2008, CELL MICROBIOL, V10, P1221, DOI 10.1111/j.1462-5822.2008.01146.x
hcfmusp.relation.referenceBrito MEF, 2009, TROP MED INT HEALTH, V14, P1278, DOI 10.1111/j.1365-3156.2009.02361.x
hcfmusp.relation.referenceCarneiro FP, 2009, PARASITE IMMUNOL, V31, P646, DOI 10.1111/j.1365-3024.2009.01148.x
hcfmusp.relation.referenceChen GJ, 2009, AM J PATHOL, V175, P1086, DOI 10.2353/ajpath.2009.080488
hcfmusp.relation.referenceDarrah PA, 2010, J EXP MED, V207, P1421, DOI 10.1084/jem.20092532
hcfmusp.relation.referenceDunning O, 2009, BIOSCI HORIZ, V2, P73
hcfmusp.relation.referenceFilippi CM, 2008, DIABETES, V57, P2684, DOI 10.2337/db08-0609
hcfmusp.relation.referenceIvory C, 2004, GENET VACCINES THER, V2, P17, DOI 10.1186/1479-0556-2-17
hcfmusp.relation.referenceKang JS, 2009, TRENDS CELL BIOL, V19, P385, DOI 10.1016/j.tcb.2009.05.008
hcfmusp.relation.referenceKaufmann SHE, 1999, IMMUNOL LETT, V65, P81, DOI 10.1016/S0165-2478(98)00128-X
hcfmusp.relation.referenceKREUTZER RD, 1991, AM J TROP MED HYG, V44, P662
hcfmusp.relation.referenceLAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
hcfmusp.relation.referenceLAINSON R, 1989, ANN PARASIT HUM COMP, V64, P200
hcfmusp.relation.referenceLAINSON R, 1989, ANN PARASIT HUM COMP, V64, P3
hcfmusp.relation.referenceLemesre JL, 2007, VACCINE, V25, P4223, DOI 10.1016/j.vaccine.2007.02.083
hcfmusp.relation.referenceLemesre JL, 2005, VACCINE, V23, P2825, DOI 10.1016/j.vaccine.2004.11.061
hcfmusp.relation.referenceLIEW FY, 1990, J IMMUNOL, V145, P4306
hcfmusp.relation.referenceNagill R, 2009, PARASITOL INT, V58, P359, DOI 10.1016/j.parint.2009.07.008
hcfmusp.relation.referenceNaundorf S, 2009, EUR J IMMUNOL, V39, P1066, DOI 10.1002/eji.200838773
hcfmusp.relation.referenceNovoa R, 2011, PARASITE IMMUNOL, V33, P132, DOI 10.1111/j.1365-3024.2010.01256.x
hcfmusp.relation.referenceO'Daly JA, 2010, ARCH DERMATOL RES, V302, P95, DOI 10.1007/s00403-009-0992-0
hcfmusp.relation.referenceO'Daly JA, 2009, ARCH DERMATOL RES, V301, P411, DOI 10.1007/s00403-009-0940-z
hcfmusp.relation.referenceO'Daly JA, 2010, ARCH DERMATOL RES, V302, P567, DOI 10.1007/s00403-009-1026-7
hcfmusp.relation.referenceO'Daly JA, 2009, ARCH DERMATOL RES, V301, P1, DOI 10.1007/s00403-008-0883-9
hcfmusp.relation.referenceO'Daly JA, 2011, ARCH DERMATOL RES, V303, P399, DOI 10.1007/s00403-011-1133-0
hcfmusp.relation.referenceOkwor I, 2008, IMMUNOL RES, V41, P123, DOI 10.1007/s12026-008-8016-2
hcfmusp.relation.referencePassero LFD, 2009, PARASITOL RES, V105, P1741, DOI 10.1007/s00436-009-1614-7
hcfmusp.relation.referencePassero LFD, 2010, PARASITOL INT, V59, P159, DOI 10.1016/j.parint.2009.12.010
hcfmusp.relation.referencePassero LFD, 2010, APMIS, V118, P973, DOI 10.1111/j.1600-0463.2010.02679.x
hcfmusp.relation.referenceRodrigues OR, 2009, IMMUNOBIOLOGY, V214, P101, DOI 10.1016/j.imbio.2008.07.001
hcfmusp.relation.referenceRodrigues OR, 2006, CELL IMMUNOL, V243, P118, DOI 10.1016/j.cellimm.2007.01.005
hcfmusp.relation.referenceRodriguez-Cortees A, 2007, VACCINE, V25, P7962, DOI 10.1016/j.vaccine.2007.08.023
hcfmusp.relation.referenceRosa R, 2005, EXP PARASITOL, V109, P106, DOI 10.1016/j.exppara.2004.11.008
hcfmusp.relation.referenceRosa R, 2007, VACCINE, V25, P4525, DOI 10.1016/j.vaccine.2007.03.003
hcfmusp.relation.referenceSantarem N, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/85154
hcfmusp.relation.referenceShanmugasundaram R, 2010, VET IMMUNOL IMMUNOP, V137, P161, DOI 10.1016/j.vetimm.2010.04.017
hcfmusp.relation.referenceSHAW JJ, 1991, ANN PARASIT HUM COMP, V66, P243
hcfmusp.relation.referenceSilveira FT, 2004, MEM I OSWALDO CRUZ, V99, P239, DOI 10.1590/S0074-02762004000300001
hcfmusp.relation.referenceSilveira FT, 2002, PARASITE, V9, P43
hcfmusp.relation.referenceSouza-Lemos C, 2008, J PATHOL, V216, P375, DOI 10.1002/path.2403
hcfmusp.relation.referenceTaylor AW, 2009, J LEUKOCYTE BIOL, V85, P29, DOI 10.1189/jlb.0708415
hcfmusp.relation.referenceTonui WK, 2004, INFECT IMMUN, V72, P5654, DOI 10.1128/IAI.72.10.5654-5661.2004
hcfmusp.relation.referenceWolff J, 1990, SCIENCE, V1247, P1465
hcfmusp.remissive.sponsorshipEuropean Union
hcfmusp.remissive.sponsorshipFAPESP
hcfmusp.remissive.sponsorshipFMUSP-HC
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication89c201f0-f765-4604-9a5d-ad24066d3839
relation.isAuthorOfPublicationc3fb7e3f-2b41-411b-8998-4eb53ce352ca
relation.isAuthorOfPublicationd3c4405d-684f-40bd-a509-cca8e57f1705
relation.isAuthorOfPublication.latestForDiscovery89c201f0-f765-4604-9a5d-ad24066d3839
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_PASSERO_Analysis_of_the_protective_potential_of_antigens_released_2012.PDF
Tamanho:
500.22 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - LIM/50